Phase I Dose Escalation Study to Investigate the Safety of ISTH0036 in Subjects With Glaucoma Undergoing Trabeculectomy
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This study evaluates the addition of ISTH0036, an antisense oligonucleotide against TGF-β2,
to glaucoma filtration surgery (trabeculectomy). The treatment aims at improving the surgery
outcome by prevention of excessive scarring and trabecular meshwork transformation.